Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa

This study has been terminated.
(See termination reason in detailed description.)
Information provided by (Responsible Party):
Pfizer Identifier:
First received: April 7, 2010
Last updated: April 14, 2014
Last verified: April 2014

The study will be conducted in asymptomatic pregnant women with P. falciparum parasitemia. The subjects will be given 3 day dosing regiment of the fixed-dose combination of Azithromycin and Chloroquine. Parasitological clearance rate with polymerase chain reaction data will be evaluated on Day 28 as primary endpoint.

Condition Intervention Phase
Asymptomatic Parasitemia In Pregnancy
Drug: Azithromycin plus chloroquine
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Non Comparative Study To Evaluate Parasitological Clearance Rates And Pharmacokinetics Of Azithromycin And Chloroquine Following Administration Of A Fixed Dose Combination Of Azithromycin And Chloroquine (AZCQ) In Asymptomatic Pregnant Women With Plasmodium Falciparum Parasitemia In Sub Saharan Africa

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Parasitological response (PCR corrected) at Day 28 post first dose of study medication. [ Time Frame: Day 28 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Parasitological responses (PCR corrected) [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR corrected) [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR corrected) [ Time Frame: Day 21 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR corrected) [ Time Frame: Day 35 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR corrected) [ Time Frame: Day 42 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR uncorrected) [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR uncorrected) [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR uncorrected) [ Time Frame: Day 21 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR uncorrected) [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR uncorrected) [ Time Frame: Day 35 ] [ Designated as safety issue: No ]
  • Parasitological responses (PCR uncorrected) [ Time Frame: Day 42 ] [ Designated as safety issue: No ]
  • Parasite counts at each visit - number of asexual P. falciparum parasites per microliter of blood. [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Parasite counts at each visit - number of asexual P. falciparum parasites per microliter of blood. [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
  • Parasite counts at each visit - number of asexual P. falciparum parasites per microliter of blood. [ Time Frame: Day 21 ] [ Designated as safety issue: No ]
  • Parasite counts at each visit - number of asexual P. falciparum parasites per microliter of blood. [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
  • Parasite counts at each visit - number of asexual P. falciparum parasites per microliter of blood. [ Time Frame: Day 35 ] [ Designated as safety issue: No ]
  • Parasite counts at each visit - number of asexual P. falciparum parasites per microliter of blood. [ Time Frame: Day 42 ] [ Designated as safety issue: No ]

Enrollment: 168
Study Start Date: March 2011
Study Completion Date: October 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZCQ
Drug: Azithromycin plus chloroquine
Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
Other Name: Zithromax; Aralen

Detailed Description:

After interim analysis of efficacy data by an External Data Monitoring Committee, this study was terminated. Investigators were notified on 22 Aug 2013. There were no safety concerns that led to this termination.


Ages Eligible for Study:   16 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primigravidae and secundigravidae pregnant women at >=14 and <=30 weeks of gestational age (confirmed by ultrasound examination).
  • Evidence of asymptomatic parasitemia with Plasmodium falciparum monoinfection (confirmed by microscopy) with parasite counts in the range of 80 100,000/uL on thick blood smears.
  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative if a subject is <18 years of age) has been informed of all pertinent aspects of the study and that all questions by the subject have been sufficiently answered. Assent will be obtained from subjects <18 years of age.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Age <16 years old or >35 years old.
  • Multiple gestations (more than one fetus) as per the ultrasound results at screening.
  • Clinical symptoms of malaria.
  • Hemoglobin <8 g/dL (measured at baseline).
  • Any condition requiring hospitalization or evidence of severe concomitant infection at time of presentation.
  • Use of antimalarial drugs in previous 4 weeks.
  • History of convulsions, hypertension, diabetes or any other chronic illness that may adversely affect fetal growth and viability.
  • Known allergy to the study drugs (AZ, CQ, and SP) or to any macrolides or sulphonamides.
  • Requirement to use medication during the study that might interfere with the evaluation of the study drug of AZ or CQ or is contra indicated during pregnancy per package inserts.
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Evidence of current obstetric complications that may adversely impact the pregnancy and/or fetal outcomes, including presence of congenital anomalies, placenta previa or abruption.
  • Known severe sickle cell (SS) disease or sickle hemoglobin C (SC) anemia.
  • Known family history of prolonged QT syndrome, serious ventricular arrhythmia, or sudden cardiac death.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01103713

Centre de Sante d'AHOUANSORI -AGUE
Cotonou, Benin
Hôpital Bethesda
Cotonou, Benin
Siaya District Hospital
Siaya, Kenya
Zomba Central Hospital
Zomba, Malawi
Teule Hospital
Muheza, Tanga, Tanzania
National Institute for Medical Research (Mwanza Centre)/ Nyamagana District Hospital
Mwanza, Tanzania
Mulanda Health Centre IV
Kampala, Uganda
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT01103713     History of Changes
Other Study ID Numbers: A0661201
Study First Received: April 7, 2010
Last Updated: April 14, 2014
Health Authority: Kenya: Ministry of Health
Tanzania: Food & Drug Administration

Keywords provided by Pfizer:
P. falciparum malaria
asymptomatic parasitemia
parasitological clearance
Intermittent Preventive Treatment of Falciparum Malaria in Pregnant Women (IPTp)

Additional relevant MeSH terms:
Parasitic Diseases
Pathologic Processes
Systemic Inflammatory Response Syndrome
Chloroquine diphosphate
Analgesics, Non-Narcotic
Anti-Infective Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antinematodal Agents
Antiparasitic Agents
Antiprotozoal Agents
Antirheumatic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 20, 2014